Figure 2.
OS in patients treated with targeted drugs by CLL-IPI risk factors. OS according to age (A), Binet stage (B), levels of serum β2-microglobulin (C), IGHV mutational status (D), and TP53 status (E).
OS in patients treated with targeted drugs by CLL-IPI risk factors. OS according to age (A), Binet stage (B), levels of serum β2-microglobulin (C), IGHV mutational status (D), and TP53 status (E).
